CID-2011756, discovered from an HTS-high throughput screening campaign, is a cell-permeable, ATP-competitive and specific inhibitor of PKD (protein kinase D) with potential anticancer activity. It inhibits PKD2/3/1 with IC50 values of 0.6, 0.7 and 3.2 μM, respectively. Diacylglycerol regulates a novel family of serine/threonine kinases called PKD, which is implicated in numerous cellular functions as well as a range of pathological conditions. In LNCaP prostate cancer cells, phorbol ester-induced endogenous PKD1 activation is inhibited by CID-2011756 in a concentration-dependent manner.
Physicochemical Properties
| Molecular Formula | C22H21CLN2O3 | |
| Molecular Weight | 396.87 | |
| Exact Mass | 396.124 | |
| Elemental Analysis | C, 66.58; H, 5.33; Cl, 8.93; N, 7.06; O, 12.09 | |
| CAS # | 638156-11-3 | |
| Related CAS # |
|
|
| PubChem CID | 2011756 | |
| Appearance | White to off-white solid powder | |
| Density | 1.3±0.1 g/cm3 | |
| Boiling Point | 491.0±45.0 °C at 760 mmHg | |
| Flash Point | 250.8±28.7 °C | |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C | |
| Index of Refraction | 1.633 | |
| LogP | 3.69 | |
| Hydrogen Bond Donor Count | 1 | |
| Hydrogen Bond Acceptor Count | 4 | |
| Rotatable Bond Count | 5 | |
| Heavy Atom Count | 28 | |
| Complexity | 506 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | ClC1=C([H])C([H])=C([H])C(=C1[H])C1=C([H])C([H])=C(C(N([H])C2C([H])=C([H])C(=C([H])C=2[H])C([H])([H])N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=O)O1 |
|
| InChi Key | XQJWTJLJEYIUDZ-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C22H21ClN2O3/c23-18-3-1-2-17(14-18)20-8-9-21(28-20)22(26)24-19-6-4-16(5-7-19)15-25-10-12-27-13-11-25/h1-9,14H,10-13,15H2,(H,24,26) | |
| Chemical Name | 5-(3-chlorophenyl)-N-[4-(morpholin-4-ylmethyl)phenyl]furan-2-carboxamide | |
| Synonyms | CID 2011756; CID-2011756; CID2011756 | |
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Cellular PKD2 ( IC50 = 0.6 μM ); Cellular PKD3 ( IC50 = 0.7 μM ); PKD1 ( IC50 = 3.2 μM ) | ||
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay | CID 2011756 has comparable, though not identical, potencies to pan-PKD inhibitors (PKD2 IC50 = 0.6±0.1 uM; PKD3 IC50 = 0.7±0.2 uM), as might be expected for an ATP competitive inhibitor. At 10±0.7 uM (n = 3), CID 2011756 had the highest potency among the inhibitors. This EC50 value was similar to that of benzoxoloazepinolone, which we had previously reported. | ||
| Cell Assay | In LNCaP prostate cancer cells, it inhibits endogenous PKD1 activation induced by phorbol ester in a concentration-dependent manner. | ||
| Animal Protocol |
|
||
| References |
[1]. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS One. 2011;6(10):e25134. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5197 mL | 12.5986 mL | 25.1972 mL | |
| 5 mM | 0.5039 mL | 2.5197 mL | 5.0394 mL | |
| 10 mM | 0.2520 mL | 1.2599 mL | 2.5197 mL |